Technology transfer

Vinmec's Innovations Spotlighted at Global CSR & ESG Summit 2024

Retrieved on: 
Wednesday, May 8, 2024

HANOI, Vietnam, May 9, 2024 - (ACN Newswire) - The 16th Annual Global CSR & ESG Summit & Awards 2024 was held on April 25 in Hanoi, Vietnam.

Key Points: 
  • HANOI, Vietnam, May 9, 2024 - (ACN Newswire) - The 16th Annual Global CSR & ESG Summit & Awards 2024 was held on April 25 in Hanoi, Vietnam.
  • The event showcased tremarkable strides in corporate social responsibility (CSR) and environmental, social, and governance (ESG) initiatives, and featured some of the most outstanding achievements by enterprises and organizations in this regard.
  • ACN: Can you share with us the vision and mission of Vinmec, particularly its dedication to academic healthcare for people at local and global scales?
  • Our emphasis on cutting-edgeinnovative applications like 3D printing and robotic surgery ensures clinical excellence and value-based solutions for our patients.

EQS-News: Biotest increased sales by 83.6% to Euro 215.2 million in first quarter 2024

Retrieved on: 
Friday, May 10, 2024

The Biotest Group recorded revenue of € 215.2 million in the first quarter of the 2024 financial year.

Key Points: 
  • The Biotest Group recorded revenue of € 215.2 million in the first quarter of the 2024 financial year.
  • EBIT for the first quarter of 2024 amounted to € 52.8 million, a significant improvement on the first quarter of the previous year (prior year period: € - 9.1 million).
  • The financial result for the first quarter of the current year deteriorated by € -1.4 million to € -10.7 million (prior-year period: € -9.3 million).
  • The Biotest Group's earnings after taxes improved to € 29.5 million in the first quarter of 2024 after € -20.4 million in the same quarter of the previous year due to the influencing factors described above.

MeiraGTx Reports First Quarter 2024 Financial and Operational Results

Retrieved on: 
Thursday, May 9, 2024

LONDON and NEW YORK, May 09, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced financial and operational results for the first quarter ended March 31, 2024, and provided a corporate update.

Key Points: 
  • MeiraGTx anticipates receiving an additional $15 million in near-term milestone payments later in 2024.
  • As of March 31, 2024, MeiraGTx had cash and cash equivalents of approximately $119.2 million and in April 2024, the Company collected $19.7 million in receivables which were due in the first quarter of 2024, effectively increasing the cash balance to $138.9 million.
  • The increase of $0.6 million was due to higher interest rates and cash balances during 2024.
  • Interest expense was $3.3 million for the three months ended March 31, 2024, compared to $3.1 million for the three months ended March 31, 2023.

Solid Power First Quarter 2024 Results Reflect Continued Progress Towards 2024 Goals

Retrieved on: 
Tuesday, May 7, 2024

ET today

Key Points: 
  • ET today
    LOUISVILLE, Colo., May 07, 2024 (GLOBE NEWSWIRE) -- Solid Power, Inc. (Nasdaq: SLDP), a leading developer of solid-state battery technology, today announced its operational and financial results for the first quarter of 2024.
  • We continue to target delivery of A-2 Sample cells by the end of the year,” Van Scoter continued.
  • This increase was driven by continued execution under the company’s joint development agreements and other collaborative arrangements.
  • First quarter 2024 operating loss was $25.8 million and net loss was $21.2 million, or $0.12 per share.

SentrySciences Signs Collaboration Agreement with Coriolis Pharma

Retrieved on: 
Tuesday, May 7, 2024

LONGMONT, Colo., May 7, 2024 /PRNewswire-PRWeb/ -- ParticleSentryAI software employs deep machine learning to analyze images of subvisible particles in biopharmaceutical products and provides actionable data and insight during formulation development, scale-up, manufacturing and technology transfer. Historically, subvisible particle images from platforms like flow imaging microscopy and microfluidic imaging have been underutilized because the morphological representations of the particles were not readily accessible and easily comparable. ParticleSentryAI software leverages the morphological and textural features encoded in the images to assist in determining the causes of protein aggregation and delivers actionable data to limit their impact. The software delivers a fingerprint that characterizes the particle populations. Embedded statistical processes demonstrate changes in the fingerprint when compared against other samples. Comparisons can be applied to confirm batch-to-batch consistency, before and after results at critical processes and many other applications in biopharmaceutical development and manufacturing.

Key Points: 
  • SentrySciences proudly announces a recent collaboration agreement with Coriolis Pharma.
  • Within the scope of a pilot phase, Coriolis will act as the exclusive service provider for SentrySciences' ParticleSentryAI software analysis services in Europe.
  • Coriolis considers this collaboration agreement as an excellent opportunity to advance its efforts to integrate innovative digital formulation approaches and to complement its own particle analysis offering with an AI-based service.
  • Coriolis will benefit from upcoming new features of ParticleSentryAI software, while SentrySciences continue to drive the development of this new technology.

Khalifa University's RIC2D and North America-based HydroGraph Clean Power Sign MoU to Collaborate on Research Projects and Expedite Commercialization

Retrieved on: 
Monday, April 15, 2024

ABU DHABI, United Arab Emirates, April 15, 2024 (GLOBE NEWSWIRE) -- Khalifa University of Science and Technology’s Research and Innovation Center in Graphene and 2D Materials (RIC2D) and HydroGraph Clean Power Inc .

Key Points: 
  • ABU DHABI, United Arab Emirates, April 15, 2024 (GLOBE NEWSWIRE) -- Khalifa University of Science and Technology’s Research and Innovation Center in Graphene and 2D Materials (RIC2D) and HydroGraph Clean Power Inc .
  • The MoU between Khalifa University’s RIC2D and HydroGraph was signed by Dr. Hassan Arafat, senior director, RIC2D; and Kjirstin Breure, president and interim CEO, HydroGraph.
  • According to the MoU, the partners aim to facilitate knowledge exchange, joint research projects and technology transfer in graphene production and supply.
  • RIC2D leads in engaging with stakeholders for advancing the use of graphene and nanomaterials for various applications.

Kraig Biocraft Laboratories Announces Successful Launch of Spring Production Trials in Southeast Asia for Spider Silk

Retrieved on: 
Monday, April 15, 2024

The Company successfully launched the production trials of BAM-1, its newest and most robust recombinant spider silk production silkworm hybrid, on time and in line with its production roadmap.

Key Points: 
  • The Company successfully launched the production trials of BAM-1, its newest and most robust recombinant spider silk production silkworm hybrid, on time and in line with its production roadmap.
  • The Company's CEO remains in Asia to directly oversee the production trial of the BAM-1 parental strains and monitor their performance.
  • "Our team invested heavily in improving the robustness of our production recombinant spider silk strains based on hard lessons learned and the testing data collected in 2023.
  • To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news .

New Study by Invent Together Finds Building Trust Is Key Driver for Inventing and Patenting, Especially for Women and People of Color

Retrieved on: 
Wednesday, May 1, 2024

The study also identified significant trust gaps among women and people of color, which deter their participation in inventing and patenting.

Key Points: 
  • The study also identified significant trust gaps among women and people of color, which deter their participation in inventing and patenting.
  • Black and Hispanic women are at the greatest disadvantage, with 88% of Hispanic and 86% of Black women reporting minimal or no knowledge.
  • Purpose-driven innovation: Women and people of color are often motivated to invent to benefit their communities or solve a societal problem.
  • This study will help stakeholders better understand and address the complex dynamics influencing engagement in inventing and patenting.

Ferring Pharmaceuticals and SK Pharmteco Enter into Commercial Gene Therapy Manufacturing Deal

Retrieved on: 
Thursday, April 18, 2024

Ferring Pharmaceuticals and SK pharmteco today announced an agreement to scale up commercial manufacturing capacity for the drug substance of Ferring’s intravesical non-replicating gene therapy ADSTILADRIN (nadofaragene firadenovec-vncg) for ensuring long-term future supply.

Key Points: 
  • Ferring Pharmaceuticals and SK pharmteco today announced an agreement to scale up commercial manufacturing capacity for the drug substance of Ferring’s intravesical non-replicating gene therapy ADSTILADRIN (nadofaragene firadenovec-vncg) for ensuring long-term future supply.
  • This additional scale up and diversification of drug substance capacity demonstrates Ferring’s commitment to securing future long-term supply of ADSTILADRIN to meet the projected commercial growth of its non-replicating gene therapy.
  • “Ferring takes its responsibilities to patients with high-risk BCG-unresponsive NMIBC very seriously – especially when pioneering in the emerging field of gene therapy commercial manufacturing,” said Bipin Dalmia, Global Head, Uro-Oncology Franchise, Ferring Pharmaceuticals.
  • In the United States, it is the seventh most common cancer, fourth among men,3-4 and 75% of bladder cancer presents as NMIBC.5
    “SK pharmteco is proud to partner with Ferring Pharmaceuticals as a manufacturer of the breakthrough gene therapy ADSTILADRIN,” said Joerg Ahlgrimm, Chief Executive Officer for SK pharmteco.

HKUST President Leads Delegation to UAE Securing Partnerships on Research, Tech Transfer and Talent Development

Retrieved on: 
Monday, April 22, 2024

Led by HKUST President Prof. Nancy IP, the delegation established valuable ties and partnerships with prominent institutions in the United Arab Emirates (UAE) to foster education, research, and innovation.

Key Points: 
  • Led by HKUST President Prof. Nancy IP, the delegation established valuable ties and partnerships with prominent institutions in the United Arab Emirates (UAE) to foster education, research, and innovation.
  • This is the first visit from Hong Kong's higher education sector following Hong Kong Chief Executive John LEE's delegation to the region last year.
  • Discussions focused on research collaboration, technology transfer, and talent development in cutting-edge fields such as artificial intelligence (AI), robotics, medical technology, clean energy, and start-up incubation.
  • During the visit, HKUST delegate Prof. Wang Yang, representing HKUST as the Executive President of the Asian Universities Alliance (AUA), also attended the AUA President Forum hosted by the UAE University.